Ola Wlodek, a Chief Operating Officer at Reflection Therapeutics, has a PhD in mitochondrial biology from Cambridge University, and studies executive MBA at Warwick Business School. After her PhD, she spent five years at Isomerase Therapeutics, where she worked in a range of research roles, before co-founding Reflection Therapeutics, a Cambridge-based company developing a new cell therapy for amyotrophic lateral sclerosis.
Reason for joining the NGWC:
"I am incredibly excited to join the inaugural Ovarian Cancer Action Next Generation Women's Collective - especially at this difficult time for all the research charities. Through the NGWC initiative I am committed to raise funds for life-saving ovarian cancer research, alongside the other inspiring women of NGWC, and I am very grateful for this opportunity."
Linkedin: Ola Wlodek